auto-fix: strip 4 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -91,7 +91,7 @@ WHO's conditional recommendation structure and behavioral therapy requirement su
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
+*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-18*
 
 If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), then the chronic use assumption may be wrong. Patients who establish exercise habits during a 1-2 year medication window may not need indefinite treatment, fundamentally changing the cost trajectory. The inflationary projection assumes continuous medication; the combination data suggests a time-limited intervention model may be viable.
 

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -50,7 +50,7 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
 
 Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
 

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -36,7 +36,7 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
 
 
 ### Additional Evidence (confirm)
-*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
 
 SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
 

domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md

@@ -33,7 +33,7 @@ The composition of spending shifts dramatically: less on chronic disease managem
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-23-cbo-medicare-trust-fund-2040-insolvency]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2026-02-23-cbo-medicare-trust-fund-2040-insolvency | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 (extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.